US to allow states to distribute Gilead’s remdesivir to fight COVID-19

REUTERS: The US Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United States would receive about 40 per cent of the drug maker's global donation.

Gilead has committed to supply approximately 607,000 vials of remdesivir over the next six weeks in the United States, and the US state health department will distribute the doses to appropriate hospitals in their states, HHS said.

Advertisement

Advertisement

Gilead's drug has shown promise in helping patients infected with COVID-19, the illness caused by the novel coronavirus, and is being closely watched on how the limited supply is distributed.

Last Friday, the US Food and Drug Administration gave emergency use authorization for the drug for patients with severe COVID-19, clearing the way for broader use in more hospitals around the United States.

Data has shown Gilead's antiviral drug remdesivir helped to reduce hospital stays for COVID-19 patients.

Gilead Chief Executive Dan O'Day said in late April that Gilead would donate 1.5 million doses and work with the US government on distribution.

Advertisement

Advertisement

On Saturday, HHS said the 1.5 million doses were a global figure and that 607,000 would be distributed through the agency.

The allocation by Gilead Sciences to the United States was finalised on May 3, HHS said.

The US is sending the drug remdesivir to local agencies in Illinois, Iowa, Connecticut, Maryland, Michigan and New Jersey.

Gilead did not immediately respond to a request for comment.

The Infectious Disease Society of America (IDSA) on Thursday said it is asking for more information on the federal government's plan for deciding how and where to distribute the drug.

The federal government began distributing the drug this week but doctors across the country, particularly in COVID-19 hotspots like New York and Boston, became concerned after being denied their request to obtain the new therapy, IDSA president Dr Thomas File told Reuters on Thursday.

The IDSA on Wednesday called on the Trump Administration to explain how it Read More – Source